





## **Supplementary Materials**





**Figure S1.** Effect of EA on the activation of oligodendrocytes in the corpus callosum. **(A)** Fluorescence staining against Olig2 (green) and BrdU (red) after EA (3mA) treatment. Scale bar = 100  $\mu$ m. **(B)** Immunofluorescence staining against Olig2 (green) and CC1 (red) after EA (3mA) treatment. Scale bar = 100  $\mu$ m. **(C)** The number of Olig2<sup>+</sup>/BrdU<sup>+</sup> cells and Olig2<sup>+</sup>/CC1<sup>+</sup> cells. Olig2<sup>+</sup>/BrdU<sup>+</sup> cells and Olig2<sup>+</sup>/CC1<sup>+</sup> cells were increased in the EA group. Data presented as mean ± SEM. \**P* < 0.05, \*\**P* < 0.01 and \*\*\**P* < 0.001 *vs.* sham. Olig2 (NBP1-28667, Novus Biologicals, Littleton, USA); and CC1 (GTX16794, APC antibody, Gentex Corp., CA, USA).